Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The human epidermal growth factor receptor (HER/ErbB) family consists of four closely related transmembrane tyrosine kinase receptors: HER1 (EGFR/ErbB1), HER2 (ErbB2/neu), HER3 (ErbB3), and HER4 (ErbB4). Dimerization among these receptors—either as homodimers or heterodimers—is a critical event for their activation, leading to downstream signaling that regulates cell proliferation, survival, differentiation, and other processes relevant to cancer biology. Overexpression/amplification of these receptors—especially HER2—is implicated in various cancers and serves as a therapeutic target.
Tyrosine kinase inhibition, Receptor dimerization inhibition, Antibody-dependent cell-mediated cytotoxicity (ADCC)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Epidermal Growth Factor Receptor family (HER/ErbB family).